Pasi A Ja Nne

List of Publications by Citations

355 papers	73,534 citations	116 h-index	269 g-index
402 ext. papers	84,096 ext. citations	12.2 avg, IF	7.5 L-index

#	Paper	IF	Citations
355	EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science*, **2004**, 304, 1497-500	33.3	7937
354	MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. *Science*, **2007**, 316, 1039-43	33.3	3705
353	Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *New England Journal of Medicine*, **2010**, 363, 1693-703	59.2	3577
352	EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. *New England Journal of Medicine*, **2005**, 352, 786-92	59.2	3250
351	Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. *New England Journal of Medicine*, **2013**, 368, 2385-94	59.2	2594
350	The landscape of somatic copy-number alteration across human cancers. *Nature*, **2010**, 463, 899-905	50.4	2590
349	AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. *New England Journal of Medicine*, **2015**, 372, 1689-99	59.2	1447
348	Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. *Cell*, **2012**, 150, 1107-20	32.2	1304
347	Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. *Journal of Clinical Oncology*, **2005**, 23, 5900-9	2.2	1250
346	Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. *Nature Medicine*, **2015**, 21, 560-2	50.5	1021
345	Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. *Lancet Oncology, The*, **2012**, 13, 1011-9	21.7	983
344	Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. *Cancer Discovery*, **2013**, 3, 1355-63	24.4	831
343	Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. *Cancer Cell*, **2010**, 17, 77-88	24.3	816
342	EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. *Clinical Cancer Research*, **2008**, 14, 4275-83	12.9	774
341	LKB1 modulates lung cancer differentiation and metastasis. *Nature*, **2007**, 448, 807-10	50.4	774
340	Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. *Nature*, **2009**, 462, 1070-4	50.4	766
339	First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. *Journal of Clinical Oncology*, **2008**, 26, 2442-9	2.2	725

338	The quest to overcome resistance to EGFR-targeted therapies in cancer. *Nature Medicine*, **2013**, 19, 1389-400	50.5	684
337	Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. *Nature Medicine*, **2012**, 18, 382-4	50.5	664
336	Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma. *Cancer Discovery*, **2018**, 8, 822-835	24.4	648
335	Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. *New England Journal of Medicine*, **2010**, 363, 1727-33	59.2	622
334	Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. *Journal of Clinical Oncology*, **2010**, 28, 357-60	2.2	615
333	Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. *Journal of Clinical Oncology*, **2016**, 34, 3375-82	2.2	605
332	PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. *Cancer Research*, **2007**, 67, 11924-32	10.1	589
331	Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. *Clinical Cancer Research*, **2014**, 20, 1698-1705	12.9	580
330	Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. *Clinical Cancer Research*, **2008**, 14, 2895-9	12.9	576
329	Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. *Clinical Cancer Research*, **2009**, 15, 5216-23	12.9	560
328	Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. *Lancet Oncology, The*, **2013**, 14, 38-47	21.7	536
327	Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. *PLoS Medicine*, **2005**, 2, e313	11.6	527
326	Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. *Clinical Cancer Research*, **2006**, 12, 3908-14	12.9	479
325	A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. *Cancer Research*, **2011**, 71, 6051-60	10.1	468
324	Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. *Science Translational Medicine*, **2011**, 3, 99ra86	17.5	463
323	An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. *Cancer Research*, **2004**, 64, 3060-71	10.1	447
322	ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 3788-93	11.5	437
321	Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. *Nature Medicine*, **2013**, 19, 1469-1472	50.5	420

320	Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. *Nature*, **2016**, 534, 129-32	50.4	414
319	The KRAS Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. *Cancer Discovery*, **2020**, 10, 54-71	24.4	413
318	Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. *JAMA Oncology*, **2016**, 2, 1014-22	13.4	412
317	Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. *Nature Medicine*, **2014**, 20, 682-8	50.5	406
316	Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. *Clinical Cancer Research*, **2016**, 22, 5130-5140	12.9	397
315	Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. *Cancer Discovery*, **2011**, 1, 78-89	24.4	389
314	The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. *Cancer Cell*, **2006**, 9, 485-95	24.3	389
313	MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. *Journal of Clinical Oncology*, **2016**, 34, 721-30	2.2	383
312	Chemoprevention of colorectal cancer. *New England Journal of Medicine*, **2000**, 342, 1960-8	59.2	379
311	Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. *Journal of Clinical Investigation*, **2006**, 116, 2695-706	15.9	372
310	A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. *Clinical Cancer Research*, **2010**, 16, 1561-71	12.9	364
309	Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. *Journal of Clinical Oncology*, **2017**, 35, 1288-1296	2.2	363
308	A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. *Nature*, **2012**, 483, 613-7	50.4	361
307	RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. *Nature Communications*, **2015**, 6, 6377	17.4	358
306	Circumventing cancer drug resistance in the era of personalized medicine. *Cancer Discovery*, **2012**, 2, 214-26	24.4	348
305	Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. *Journal of Clinical Oncology*, **2005**, 23, 3227-34	2.2	343
304	Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. *JAMA Oncology*, **2018**, 4, 1527-1534	13.4	342
303	Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. *Clinical Cancer Research*, **2009**, 15, 5267-73	12.9	328

302	Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. *Cancer Research*, **2004**, 64, 7241-4	10.1	316
301	Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. *Journal of Clinical Oncology*, **2010**, 28, 4953-60	2.2	296
300	Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. *Journal of Clinical Oncology*, **2018**, 36, 841-849	2.2	291
299	Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. *Cancer Research*, **2005**, 65, 5561-70	10.1	285
298	Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. *Nature Medicine*, **2006**, 12, 852-5	50.5	283
297	Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses. *Clinical Cancer Research*, **2016**, 22, 1103-10	12.9	282
296	Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. *Journal of Clinical Oncology*, **2007**, 25, 760-6	2.2	279
295	Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. *Cancer Cell*, **2014**, 25, 590-604	24.3	273
294	Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. *Journal of the National Cancer Institute*, **2005**, 97, 1185-94	9.7	268
293	The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. *Cancer Research*, **2010**, 70, 10038-43	10.1	264
292	Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. *Nature Reviews Drug Discovery*, **2009**, 8, 709-23	64.1	259
291	EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors. *Clinical Cancer Research*, **2015**, 21, 3913-23	12.9	256
290	A new device for rapid isolation by size and characterization of rare circulating tumor cells. *Anticancer Research*, **2011**, 31, 427-41	2.3	256
289	Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. *Nature Genetics*, **2018**, 50, 1271-1281	36.3	249
288	New targetable oncogenes in non-small-cell lung cancer. *Journal of Clinical Oncology*, **2013**, 31, 1097-104	2.2	249
287	Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. *Clinical Cancer Research*, **2009**, 15, 3484-94	12.9	244
286	Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. *Clinical Cancer Research*, **2013**, 19, 4532-40	12.9	238
285	Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. *Cell*, **2015**, 160, 977-989	56.2	237

284	Response and acquired resistance to everolimus in anaplastic thyroid cancer. *New England Journal of Medicine*, **2014**, 371, 1426-33	59.2	237
283	A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. *Clinical Cancer Research*, **2009**, 15, 2552-8	12.9	230
282	Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. *Angewandte Chemie - International Edition*, **2014**, 53, 199-204	16.4	223
281	Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. *Journal of Clinical Oncology*, **2013**, 31, 2173-81	2.2	214
280	Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. *Cancer Discovery*, **2012**, 2, 934-47	24.4	212
279	Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2017**, 317, 1844-1853	27.4	211
278	False-Positive Plasma Genotyping Due to Clonal Hematopoiesis. *Clinical Cancer Research*, **2018**, 24, 4437-4443	12.9	210
277	Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. *Journal of Clinical Oncology*, **2006**, 24, 4517-20	2.2	210
276	Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. *Clinical Cancer Research*, **2009**, 15, 2630-6	12.9	206
275	A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. *Clinical Cancer Research*, **2006**, 12, 751-8	12.9	199
274	Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. *Journal of Clinical Oncology*, **2017**, 35, 1403-1410	2.2	198
273	Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. *Journal of Clinical Oncology*, **2007**, 25, 2248-55	2.2	198
272	Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. *Journal of Clinical Oncology*, **2012**, 30, 2063-9	2.2	197
271	Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. *Cancer Cell*, **2007**, 12, 81-93	24.3	193
270	Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. *Lung Cancer*, **2004**, 44, 221-30	5.9	185
269	Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. *Journal of Thoracic Oncology*, **2013**, 8, 179-84	8.9	182
268	Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology*, **2017**, 12, 1061-1070	8.9	178
267	Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients. *Clinical Cancer Research*, **2016**, 22, 915-22	12.9	177

266	Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. *Journal of Thoracic Oncology*, **2016**, 11, 556-65	8.9	176
265	Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. *Clinical Cancer Research*, **2006**, 12, 6049-55	12.9	173
264	Scientific Advances in Lung Cancer 2015. *Journal of Thoracic Oncology*, **2016**, 11, 613-638	8.9	164
263	Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. *Cancer Research*, **2010**, 70, 9827-36	10.1	164
262	Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. *Cancer Research*, **2011**, 71, 1081-91	10.1	164
261	Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. *Journal of Clinical Oncology*, **2006**, 24, 5253-8	2.2	163
260	Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. *Journal of Thoracic Oncology*, **2015**, 10, 1726-35	8.9	155
259	Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. *Journal of Clinical Oncology*, **2012**, 30, 2509-15	2.2	154
258	Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. *Cancer Research*, **2013**, 73, 834-43	10.1	153
257	New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. *American Journal of Roentgenology*, **2010**, 195, W221-8	5.4	153
256	Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. *Clinical Cancer Research*, **2011**, 17, 1131-9	12.9	148
255	Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. *Clinical Lung Cancer*, **2005**, 7, 40-6	4.9	147
254	Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. *Cancer Research*, **2005**, 65, 8968-74	10.1	145
253	KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS. *Cell*, **2018**, 172, 857-868.e15	56.2	142
252	Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer. *Cancer Discovery*, **2015**, 5, 960-971	24.4	142
251	Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. *Oncologist*, **2007**, 12, 90-8	5.7	138
250	Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. *Cancer Research*, **2013**, 73, 2574-86	10.1	135
249	Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. *Clinical Cancer Research*, **2008**, 14, 7060-7	12.9	135

248	Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. *Cancer Research*, **2007**, 67, 4933-9	10.1	134
247	Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. *Cancer Research*, **2005**, 65, 7525-9	10.1	130
246	A dominant-negative effect drives selection of missense mutations in myeloid malignancies. *Science*, **2019**, 365, 599-604	33.3	127
245	Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. *Journal of Thoracic Oncology*, **2009**, 4, 809-15	8.9	127
244	Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, E4869-77	11.5	125
243	A functional landscape of resistance to ALK inhibition in lung cancer. *Cancer Cell*, **2015**, 27, 397-408	24.3	123
242	Pharmacological targeting of the pseudokinase Her3. *Nature Chemical Biology*, **2014**, 10, 1006-12	11.7	123
241	Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. *Cancer*, **2002**, 95, 1528-38	6.4	119
240	EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. *Clinical Cancer Research*, **2012**, 18, 1790-7	12.9	115
239	Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. *Clinical Cancer Research*, **2009**, 15, 7502-7509	12.9	115
238	Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. *Clinical Cancer Research*, **2006**, 12, 4416s-4420s	12.9	113
237	Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer. *Cancer Immunology Research*, **2016**, 4, 289-93	12.5	112
236	Responsiveness to cetuximab without mutations in EGFR. *New England Journal of Medicine*, **2005**, 353, 208-9	59.2	111
235	Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. *Cancer Discovery*, **2019**, 9, 926-943	24.4	110
234	Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. *Journal of Thoracic Oncology*, **2010**, 5, 1382-90	8.9	110
233	Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. *Lancet Oncology, The*, **2014**, 15, 1369-78	21.7	109
232	Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer. *Clinical Cancer Research*, **2011**, 17, 2140-8	12.9	109
231	Kinase drug discovery 20 years after imatinib: progress and future directions. *Nature Reviews Drug Discovery*, **2021**, 20, 551-569	64.1	109

230	The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. *Genome Medicine*, **2016**, 8, 79	14.4	109
229	Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. *Cancer Discovery*, **2011**, 1, 608-25	24.4	108
228	Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. *Cancer Cell*, **2020**, 37, 104-122.e12	24.3	107
227	Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. *American Journal of Human Genetics*, **2016**, 98, 1051-1066	11	107
226	Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer. *JAMA Oncology*, **2016**, 2, 313-20	13.4	106
225	Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. *Clinical Cancer Research*, **2008**, 14, 6963-73	12.9	106
224	Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas. *European Respiratory Review*, **2014**, 23, 356-66	9.8	105
223	Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. *Journal of Clinical Oncology*, **2007**, 25, 3936-44	2.2	105
222	Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. *Cancer Discovery*, **2020**, 10, 688-701	24.4	104
221	Exploring Targeted Degradation Strategy for Oncogenic KRAS. *Cell Chemical Biology*, **2020**, 27, 19-31.e6	8.2	102
220	A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. *Cancer*, **2014**, 120, 1145-54	6.4	100
219	EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. *Cancer Cytopathology*, **2009**, 117, 67-72	3.9	100
218	Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. *Cancer Research*, **2009**, 69, 8341-8	10.1	100
217	A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. *Journal of Thoracic Oncology*, **2010**, 5, 1655-61	8.9	100
216	Epidermal growth factor receptor inhibition in lung cancer: status 2012. *Journal of Thoracic Oncology*, **2013**, 8, 373-84	8.9	99
215	Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. *Cancer*, **2008**, 113, 808-14	6.4	98
214	EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects. *Cancer Treatment Reviews*, **2012**, 38, 416-30	14.4	97
213	Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. *Journal of Clinical Oncology*, **2008**, 26, 3567-72	2.2	96

212	Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK). *Journal of Medicinal Chemistry*, **2018**, 61, 4249-4255	8.3	95
211	Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer. *Cancer Discovery*, **2016**, 6, 1334-1341	24.4	94
210	Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. *Cancer Discovery*, **2013**, 3, 870-9	24.4	93
209	Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. *Lancet Oncology, The*, **2014**, 15, 1433-1441	21.7	92
208	EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. *American Journal of Clinical Pathology*, **2010** , 133, 922-34	1.9	92
207	Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer. *Clinical Cancer Research*, **2008**, 14, 5941-6	12.9	92
206	Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. *Cancer Research*, **2002**, 62, 5242-7	10.1	92
205	High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines. *Oncogene*, **2004**, 23, 2716-26	9.2	91
204	Acquired Resistance to KRAS Inhibition in Cancer. *New England Journal of Medicine*, **2021**, 384, 2382-2393	59.2	91
203	Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. *Cancer Research*, **2012**, 72, 3302-11	10.1	90
202	Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. *Cancer Chemotherapy and Pharmacology*, **2016**, 77, 767-76	3.5	88
201	A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial. *Clinical Cancer Research*, **2016**, 22, 6010-6020	12.9	84
200	Oncologists' and cancer patients' views on whole-exome sequencing and incidental findings: results from the CanSeq study. *Genetics in Medicine*, **2016**, 18, 1011-9	8.1	84
199	Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition. *Cancer Research*, **2015**, 75, 4372-83	10.1	83
198	Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors. *Cancer Research*, **2017**, 77, 2712-2721	10.1	81
197	The introduction of systematic genomic testing for patients with non-small-cell lung cancer. *Journal of Thoracic Oncology*, **2012**, 7, 1767-1774	8.9	80
196	Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes. *JCI Insight*, **2016**, 1, e89014	9.9	79
195	Physical mapping and genomic structure of the Lowe syndrome gene OCRL1. *Human Genetics*, **1997** , 99, 145-50	6.3	78

194	Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. *Cancer*, **2019**, 125, 892-901	6.4	78
193	Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models. *Clinical Cancer Research*, **2017**, 23, 6661-6672	12.9	77
192	ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. *Clinical Cancer Research*, **2015**, 21, 5439-44	12.9	76
191	Integration of molecular profiling into the lung cancer clinic. *Clinical Cancer Research*, **2009**, 15, 5317-22	12.9	73
190	Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma. *Clinical Cancer Research*, **2015**, 21, 2851-60	12.9	72
189	Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C. *Cell Chemical Biology*, **2017**, 24, 1005-1016	8.1	72
188	New strategies for treatment of ALK-rearranged non-small cell lung cancers. *Clinical Cancer Research*, **2011**, 17, 7213-8	12.9	72
187	CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool. *Academic Radiology*, **2011**, 18, 54-62	4.3	69
186	Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations. *Seminars in Oncology*, **2005**, 32, S9-15	5.5	69
185	Primary Pulmonary NUT Midline Carcinoma: Clinical, Radiographic, and Pathologic Characterizations. *Journal of Thoracic Oncology*, **2015**, 10, 951-9	8.9	68
184	Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors. *Clinical Cancer Research*, **2013**, 19, 3078-87	12.9	68
183	Epidermal growth factor receptor mutation testing in the care of lung cancer patients. *Clinical Cancer Research*, **2006**, 12, 4403s-4408s	12.9	68
182	Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma. *Clinical Cancer Research*, **2014**, 20, 6551-8	12.9	67
181	Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target. *Clinical Cancer Research*, **2012**, 18, 3737-42	12.9	64
180	TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation. *Molecular Cancer Therapeutics*, **2010**, 9, 2785-92	6.1	64
179	Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor resistant non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2014**, 32, 8009-8009	2.2	63
178	Inhibition of the met receptor in mesothelioma. *Clinical Cancer Research*, **2005**, 11, 8122-30	12.9	62
177	Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. *ESMO Open*, **2017**, 2, e000219	6	62

176	Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. *Cancer Research*, **2013**, 73, 6770-9	10.1	61
175	Ultra deep sequencing detects a low rate of mosaic mutations in tuberous sclerosis complex. *Human Genetics*, **2010**, 127, 573-82	6.3	61
174	Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours. *Lung Cancer*, **2008**, 60 Suppl 2, S3-9	5.9	61
173	Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC. *Clinical Cancer Research*, **2020**, 26, 2615-2625	12.9	60
172	Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors. *Lung Cancer*, **2014**, 86, 241-6	5.9	60
171	Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways. *Clinical Cancer Research*, **2012**, 18, 380-91	12.9	59
170	Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer. *Clinical Cancer Research*, **2017**, 23, 204-213	12.9	57
169	Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis. *Journal of Thoracic Oncology*, **2016**, 11, 850-61	8.9	57
168	Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with Exon 20 Insertion Mutations from a Phase I/II Trial. *Cancer Discovery*, **2021**, 11, 1688-1699	24.4	57
167	Trastuzumab Deruxtecan in -Mutant Non-Small-Cell Lung Cancer. *New England Journal of Medicine*, **2021**,	59.2	57
166	KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. *ELife*, **2017**, 6,	8.9	56
165	Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification. *Cancer Science*, **2010**, 101, 167-72	6.9	56
164	Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome. *Clinical Cancer Research*, **2017**, 23, 5737-5744	12.9	55
163	Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors. *Cancer Immunology Research*, **2016**, 4, 1038-1048	12.5	54
162	Discovery of selective irreversible inhibitors for EGFR-T790M. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 638-43	2.9	54
161	Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. *Lung Cancer*, **2019**, 133, 96-102	5.9	53
160	The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity. *Cancer Immunology Research*, **2019**, 7, 1457-1471	12.5	53
159	Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. *Cancer Immunology Research*, **2015**, 3, 855-63	12.5	53

158	Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study. *Clinical Cancer Research*, **2018**, 24, 1546-1553	12.9	52
157	Coamplification at lower denaturation temperature-PCR increases mutation-detection selectivity of TaqMan-based real-time PCR. *Clinical Chemistry*, **2009**, 55, 748-56	5.5	51
156	Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer. *Clinical Cancer Research*, **2016**, 22, 3148-56	12.9	49
155	Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance. *Clinical Cancer Research*, **2014**, 20, 1204-1211	12.9	49
154	Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression. *Cancer Letters*, **2009**, 282, 14-24	9.9	49
153	Increased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage disease. *PLoS ONE*, **2014**, 9, e95303	3.7	47
152	Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer?. *Clinical Cancer Research*, **2008**, 14, 3860-6	12.9	47
151	Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma. *Journal of Clinical Oncology*, **2008**, 26, 1465-71	2.2	46
150	Pemetrexed Alone or in Combination with Cisplatin in Previously Treated Malignant Pleural Mesothelioma: Outcomes from a Phase IIIB Expanded Access Program. *Journal of Thoracic Oncology* , **2006**, 1, 506-512	8.9	46
149	Patterns of failure following surgical resection for malignant pleural mesothelioma. *Thoracic Surgery Clinics*, **2004**, 14, 567-73	3.1	46
148	TGF□pathway inhibition in the treatment of non-small cell lung cancer. *Pharmacology & Therapeutics*, **2018**, 184, 112-130	13.9	46
147	Clinical Implications of Variant ALK FISH Rearrangement Patterns. *Journal of Thoracic Oncology*, **2015**, 10, 1648-52	8.9	44
146	Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification. *Clinical Cancer Research*, **2009**, 15, 907-13	12.9	44
145	Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines. *Molecular Oncology*, **2015**, 9, 260-9	7.9	43
144	Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions.. *Journal of Clinical Oncology*, **2019**, 37, 9007-9007	2.2	43
143	Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study. *Journal of Thoracic Oncology*, **2016**, 11, 737-747	8.9	42
142	Amplification of Wild-type Imparts Resistance to Crizotinib in Exon 14 Mutant Non-Small Cell Lung Cancer. *Clinical Cancer Research*, **2018**, 24, 5963-5976	12.9	42
141	Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. *JAMA Oncology*, **2019**, 5, 1448-1455	13.4	42

140	Pemetrexed Alone or in Combination with Cisplatin in Previously Treated Malignant Pleural Mesothelioma: Outcomes from a Phase IIIB Expanded Access Program. *Journal of Thoracic Oncology* , **2006**, 1, 506-512	8.9	42
139	Chemotherapy for malignant pleural mesothelioma. *Clinical Lung Cancer*, **2003**, 5, 98-106	4.9	42
138	EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib. *Journal of Thoracic Oncology*, **2017**, 12, 1247-1256	8.9	40
137	Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer. *Investigational New Drugs*, **2015**, 33, 1108-14	4.3	39
136	A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing. *Cancer Immunology Research*, **2018**, 6, 1511-1523	12.5	39
135	Development of small molecules targeting the pseudokinase Her3. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 3382-9	2.9	38
134	Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI. *Journal of Thoracic Oncology*, **2013**, 8, 1059-68	8.9	38
133	Disrupted sperm function and fertilin beta processing in mice deficient in the inositol polyphosphate 5-phosphatase Inpp5b. *Developmental Biology*, **2001**, 240, 641-53	3.1	38
132	Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study. *Lung Cancer*, **2018**, 126, 72-79	5.9	38
131	Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression. *Cancer*, **2013**, 119, 3761-8	6.4	37
130	c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential. *Melanoma Research*, **2012**, 22, 123-32	3.3	37
129	Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer. *Cancer*, **2015**, 121, 2570-7	6.4	35
128	Fulminant hepatic failure secondary to erlotinib. *Clinical Gastroenterology and Hepatology*, **2007**, 5, 917-20	6.9	35
127	Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study. *Genetics in Medicine*, **2017**, 19, 787-795	8.1	34
126	A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). *Journal of Thoracic Oncology*, **2015**, 10, 143-7	8.9	34
125	EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples. *Journal of Thoracic Oncology*, **2019**, 14, 1995-2002	8.9	34
124	Imaging of lung cancer in the era of molecular medicine. *Academic Radiology*, **2011**, 18, 424-36	4.3	33
123	Evaluating TBK1 as a therapeutic target in cancers with activated IRF3. *Molecular Cancer Research*, **2014**, 12, 1055-66	6.6	32

122	Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib. *Clinical Cancer Research*, **2021**, 27, 34-42	12.9	32
121	Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors. *Journal of Thoracic Oncology*, **2014**, 9, 316-23	8.9	31
120	RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0. *American Journal of Roentgenology*, **2013**, 201, W64-71	5.4	31
119	Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. *Journal of Medicinal Chemistry*, **2015**, 58, 9296-9308	8.3	30
118	A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer. *Cancer Chemotherapy and Pharmacology*, **2017**, 79, 923-932	3.5	29
117	U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors. *Clinical Cancer Research*, **2020**, 26, 4785-4794	12.9	29
116	Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer. *Clinical Cancer Research*, **2006**, 12, 4436s-4440s	12.9	29
115	Mutant-Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant Mutations. *Angewandte Chemie - International Edition*, **2020**, 59, 14481-14489	16.4	28
114	Discovery of 3,5-Diamino-1,2,4-triazole Ureas as Potent Anaplastic Lymphoma Kinase Inhibitors. *ACS Medicinal Chemistry Letters*, **2011**, 2, 379-384	4.3	27
113	Targeting Dysregulation in Cancer. *Cancer Discovery*, **2020**, 10, 922-934	24.4	26
112	Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2. *Cancer Research*, **2015**, 75, 3139-46	10.1	26
111	Zeroing in on ROS1 rearrangements in non-small cell lung cancer. *Clinical Cancer Research*, **2012**, 18, 4222-4	12.9	26
110	Ras pathway activation in malignant mesothelioma. *Journal of Thoracic Oncology*, **2007**, 2, 789-95	8.9	26
109	Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors. *Cancer Immunology Research*, **2015**, 3, 1333-1343	12.5	25
108	Study Design and Rationale for a Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Selumetinib in Combination With Docetaxel as Second-Line Treatment in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer (SELECT-1). *Clinical Lung Cancer*, **2016**, 17, e1-4	4.9	25
107	Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors. *ACS Medicinal Chemistry Letters*, **2019**, 10, 1549-1553	4.3	25
106	Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer. *Cancer*, **2014**, 120, 2289-98	6.4	25
105	Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells. *Bioscience Reports*, **2012**, 32, 413-22	4.1	25

104	A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer. *Journal of Thoracic Oncology*, **2012**, 7, 963-72	8.9	25
103	MA16.11 CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC: Pooled Data from Two Phase II Trials. *Journal of Thoracic Oncology*, **2017**, 12, S440-S441	8.9	24
102	Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program. *Lung Cancer*, **2007**, 55, 187-94	5.9	24
101	Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC **2020**, 8,		24
100	Enhanced ratio of signals enables digital mutation scanning for rare allele detection. *Journal of Molecular Diagnostics*, **2015**, 17, 284-92	5.1	23
99	CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC. *Cancer Research*, **2019**, 79, 4439-4452	10.1	23
98	Overcoming therapy resistance in EGFR-mutant lung cancer.. *Nature Cancer*, **2021**, 2, 377-391	15.4	23
97	Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer. *Clinical Cancer Research*, **2017**, 23, 2367-2373	12.9	22
96	Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancer. *Journal of Thoracic Oncology*, **2014**, 9, 126-31	8.9	22
95	A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers. *Cancer Cell*, **2020**, 37, 705-719.e6	24.3	21
94	Molecular pathways: the basis for rational combination using MEK inhibitors in KRAS-mutant cancers. *Clinical Cancer Research*, **2014**, 20, 4193-9	12.9	20
93	s-RT-MELT for rapid mutation scanning using enzymatic selection and real time DNA-melting: new potential for multiplex genetic analysis. *Nucleic Acids Research*, **2007**, 35, e84	20.1	20
92	Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives. *Bioorganic and Medicinal Chemistry*, **2016**, 24, 3501-12	3.4	20
91	EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib. *Journal of Thoracic Oncology*, **2017**, 12, 884-889	8.9	19
90	EGFR T790M mutation testing within the osimertinib AURA Phase I study. *Lung Cancer*, **2017**, 109, 9-13	5.9	19
89	Discovery of a potent dual ALK and EGFR T790M inhibitor. *European Journal of Medicinal Chemistry*, **2017**, 136, 497-510	6.8	19
88	Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M. *Cell Reports*, **2014**, 7, 1824-32	10.6	19
87	Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer. *Cancer Discovery*, **2021**,	24.4	19

86	Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancer. *Oral Oncology*, **2019**, 95, 120-126	4.4	18
85	Factors predicting response to EGFR tyrosine kinase inhibitors. *Seminars in Respiratory and Critical Care Medicine*, **2005**, 26, 314-22	3.9	18
84	Bronchioloalveolar carcinoma: a review of the epidemiology, pathology, and treatment. *Seminars in Respiratory and Critical Care Medicine*, **2005**, 26, 342-52	3.9	18
83	Everolimus in Anaplastic Thyroid Cancer: A Case Series. *Frontiers in Oncology*, **2019**, 9, 106	5.3	17
82	KRAS Preferentially Signals through MAPK in a RAF Dimer-Dependent Manner in Non-Small Cell Lung Cancer. *Cancer Research*, **2020**, 80, 3719-3731	10.1	17
81	Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma. *Oncology*, **2005**, 68, 500-10	3.6	17
80	A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples. *Blood*, **2006**, 107, 1237-8	2.2	17
79	Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. *Journal of Thoracic Oncology*, **2006**, 1, 506-12	8.9	17
78	Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial. *Journal of Thoracic Oncology*, **2017**, 12, 1588-1594	8.9	16
77	A phase I, open-label, dose-escalation trial of BI 1701963 as monotherapy and in combination with trametinib in patients with KRAS mutated advanced or metastatic solid tumors.. *Journal of Clinical Oncology*, **2020**, 38, TPS3651-TPS3651	2.2	15
76	Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor. *Angewandte Chemie - International Edition*, **2018**, 57, 11629-11633	16.4	15
75	Progress on Covalent Inhibition of KRAS(G12C). *Cancer Discovery*, **2016**, 6, 233-4	24.4	14
74	A severe photosensitivity dermatitis caused by crizotinib. *Journal of Thoracic Oncology*, **2014**, 9, e51-e53	8.9	14
73	MEK114653: A randomized, multicenter, phase II study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in KRAS-mutant advanced non‐small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2013**, 31, 8029-8029	2.2	14
72	Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy. *Clinical Cancer Research*, **2021**, 27, 1019-1028	12.9	14
71	First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors (KRYSTAL-1).. *Journal of Clinical Oncology*, **2022**, JCO2102752	2.2	14
70	The fuzzy world of precision medicine: deliberations of a precision medicine tumor board. *Personalized Medicine*, **2017**, 14, 37-50	2.2	13
69	Lung cancer presenting with solitary bone metastases. Case 2: acrometastasis as an initial presentation of non-small-cell lung carcinoma. *Journal of Clinical Oncology*, **1999**, 17, 2998-3001	2.2	13

68	Epidermal growth factor receptor as a novel molecular target for aggressive papillary tumors in the middle ear and temporal bone. *Oncotarget*, **2015**, 6, 11357-68	3.3	13
67	Thirty Years of HER3: From Basic Biology to Therapeutic Interventions. *Clinical Cancer Research*, **2021**, 27, 3528-3539	12.9	13
66	OA03.02 Atezolizumab as 1L Therapy for Advanced NSCLC in PD-L1 Selected Patients: Updated ORR, PFS and OS Data From the BIRCH Study. *Journal of Thoracic Oncology*, **2017**, 12, S251-S252	8.9	12
65	Use of Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for Mutant Non-Small Cell Lung Cancer. *Clinical Cancer Research*, **2020**, 26, 2393-2403	12.9	12
64	Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer. *Cancer Research*, **2011**, 71, 5965-75	10.1	12
63	Biotinylated probe isolation of targeted gene region improves detection of T790M epidermal growth factor receptor mutation via peptide nucleic acid-enriched real-time PCR. *Clinical Chemistry*, **2011**, 57, 770-3	5.5	12
62	Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas. *Lung Cancer*, **2020**, 140, 35-41	5.9	12
61	Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity. *Cancer Discovery*, **2021**, 11, 1952-1969	24.4	12
60	Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations.. *Journal of Clinical Oncology*, **2021**, 39, 9008-9008	2.2	12
59	Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial. *JAMA Oncology*, **2016**, 2, 1240-2	13.4	12
58	Isolation and characterization of circulating melanoma cells by size filtration and fluorescent in-situ hybridization. *Melanoma Research*, **2018**, 28, 89-95	3.3	11
57	Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development. *Cancer*, **2016**, 122, 3456-3463	6.4	11
56	An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFR and kit. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 4579-84	2.9	11
55	Treatment of peritoneal mesothelioma in pediatric patients. *Pediatric Blood and Cancer*, **2009**, 52, 127-9	3	11
54	Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma. *Cancer Discovery*, **2021**, 11, 2488-2505	24.4	11
53	Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer. *Journal of Clinical Oncology*, **2005**, 23, 235-7	2.2	10
52	Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer. *Oncotarget*, **2017**, 8, 92265-92274	3.3	10
51	A structural model of a Ras-Raf signalosome. *Nature Structural and Molecular Biology*, **2021**, 28, 847-857	17.6	10

50	Mutant-Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant Mutations. *Angewandte Chemie*, **2020**, 132, 14589-14597	3.6	9
49	An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer. *EBioMedicine*, **2019**, 49, 106-117	8.8	9
48	Mapping of the 75-kDa inositol polyphosphate-5-phosphatase (Inpp5b) to distal mouse chromosome 4 and its exclusion as a candidate gene for dysgenetic lens. *Genomics*, **1995**, 28, 280-5	4.3	9
47	Meningeal carcinomatosis in lung cancer. Case 2. Carcinomatous meningitis. *Journal of Clinical Oncology*, **2000**, 18, 2927-9	2.2	8
46	Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a Phase I study. *Clinical Cancer Research*, **2003**, 9, 1698-704	12.9	8
45	Power in numbers: meta-analysis to identify inhibitor-sensitive tumor genotypes. *Clinical Cancer Research*, **2013**, 19, 1634-6	12.9	7
44	An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer.. *Nature Cancer*, **2022**,	15.4	7
43	An unbiased screen for activating epidermal growth factor receptor mutations. *Journal of Biological Chemistry*, **2019**, 294, 9377-9389	5.4	6
42	Clinician Perspectives on Current Issues in Lung Cancer Drug Development. *Journal of Thoracic Oncology*, **2016**, 11, 1387-96	8.9	6
41	Phase IB Study of Osimertinib in Combination with Navitoclax in -mutant NSCLC Following Resistance to Initial Therapy (ETCTN 9903). *Clinical Cancer Research*, **2021**, 27, 1604-1611	12.9	6
40	Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations. *Molecular Oncology*, **2021**, 15, 27-42	7.9	6
39	EGFR inhibition enhances the cellular uptake and antitumor-activity of the HER3 antibody drug conjugate HER3-DXd. *Cancer Research*, **2021**,	10.1	6
38	Efficacy of Taletrectinib (AB-106/DS-6051b) in NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies. *JTO Clinical and Research Reports*, **2021**, 2, 100108	1.4	5
37	Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers.. *Nature*, **2022**,	50.4	5
36	P2.06-017 Amethyst NSCLC Trial: Phase 2 Study of MGCD265 in Patients with Advanced or Metastatic NSCLC with Activating Genetic Alterations in MET. *Journal of Thoracic Oncology*, **2017**, 12, S1080-S1081	8.9	4
35	Turnaround Time of Plasma Next-Generation Sequencing in Thoracic Oncology Patients: A Quality Improvement Analysis. *JCO Precision Oncology*, **2020**, 4,	3.6	4
34	Small-Cell Neuroendocrine Tumors: Cell State Trumps the Oncogenic Driver. *Clinical Cancer Research*, **2018**, 24, 1775-1776	12.9	4
33	Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors. *Clinical Lung Cancer*, **2018**, 19, e655-e665	4.9	4

32	Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma. *JCI Insight*, **2020**, 5,	9.9	4
31	Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC. *JCO Precision Oncology*, **2021**, 5,	3.6	4
30	Amivantamab: Treating Exon 20-Mutant Cancers With Bispecific Antibody-Mediated Receptor Degradation. *Journal of Clinical Oncology*, **2021**, 39, 3403-3406	2.2	4
29	Abemaciclib in Combination With Pembrolizumab for Stage IV -Mutant or Squamous NSCLC: A Phase 1b Study. *JTO Clinical and Research Reports*, **2021**, 2, 100234	1.4	4
28	P2.06-007 A Phase 1/2 Trial of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer (NSCLC). *Journal of Thoracic Oncology*, **2017**, 12, S1072-S1073	8.9	3
27	Impact of EGFR mutations on treatment of non-small cell lung cancer. *Cancer Chemotherapy and Pharmacology*, **2006**, 58, 5-9	3.5	3
26	The role of epidermal growth factor receptor in advanced non-small cell lung carcinoma. *Annals of Medicine*, **2003**, 35, 450-7	1.5	3
25	If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for -Mutant Lung Cancer. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	3
24	ERK Inhibitor LY3214996-Based Treatment Strategies for -Driven Lung Cancer. *Molecular Cancer Therapeutics*, **2021**, 20, 641-654	6.1	3
23	Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial.. *Journal of Thoracic Oncology*, **2022**,	8.9	3
22	P2.03b-031 Impact of PD-L1 Status on Clinical Response in SELECT-1: Selumetinib + Docetaxel in KRASm Advanced NSCLC. *Journal of Thoracic Oncology*, **2017**, 12, S952-S953	8.9	2
21	Identification of a RAS-activating Fusion in an Exceptional Responder to Sunitinib with Non-Small Cell Lung Cancer. *Clinical Cancer Research*, **2020**, 26, 4072-4079	12.9	2
20	Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor. *Angewandte Chemie*, **2018**, 130, 11803-11807	3.6	2
19	Does erlotinib improve symptoms in patients with lung cancer?. *Nature Clinical Practice Oncology*, **2007**, 4, 146-7		2
18	Concurrent docetaxel and thoracic radiation in non-small-cell lung cancer. *Clinical Lung Cancer*, **2002**, 3 Suppl 2, S37-41	4.9	2
17	Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond. *Expert Opinion on Biological Therapy*, **2021**, 21, 811-824	5.4	2
16	Plasma cfDNA Genotyping in Hospitalized Patients With Suspected Metastatic NSCLC.. *JCO Precision Oncology*, **2021**, 5, 726-732	3.6	2
15	Outcomes by , , and Genotype After Combined Modality Therapy for Locally Advanced Non-Small-Cell Lung Cancer.. *JCO Precision Oncology*, **2018**, 2, 1-18	3.6	2

List of Publications

14	Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non-Small Cell Lung or Colorectal Cancer. *JAMA Network Open*, **2021**, 4, e2117547	10.4	2
13	Prospective study of the airways and pulmonary parenchyma of patients at risk for a second lung cancer. *Clinical Cancer Research*, **2003**, 9, 5915-21	12.9	2
12	Combination of type I and type II MET tyrosine kinase inhibitors as therapeutic approach to prevent resistance. *Molecular Cancer Therapeutics*, **2021**,	6.1	1
11	Tumor Growth Rate After Nadir Is Associated With Survival in Patients With -Mutant Non-Small-Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.. *JCO Precision Oncology*, **2021**, 5, 1603-1610	3.6	1
10	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH). *Journal of Clinical Oncology*, **2017**, 35, 2781-2789	2.2	1
9	Circulating Donor-derived Cell-free DNA as a Biomarker in Vascularized Composite Allotransplantation?. *Transplantation*, **2020**, 104, e79-e80	1.8	1
8	Clinical pharmacokinetics of bdtx-189, an inhibitor of allosteric ErbB mutations, in patients with advanced solid malignancies in MasterKey-01 study.. *Journal of Clinical Oncology*, **2021**, 39, 3097-3097	2.2	1
7	Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of -mutant lung cancer. *Science Translational Medicine*, **2021**, 13, eabb3738	17.5	0
6	Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC.. *Bioorganic and Medicinal Chemistry Letters*, **2022**, 128718	2.9	0
5	Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors.. *Nature Communications*, **2022**, 13, 2530	17.4	0
4	KRAS mutation analysis helps to differentiate between pulmonary metastasis from colon adenocarcinoma in situ and primary lung adenocarcinoma. *Journal of Thoracic Oncology*, **2011**, 6, 220-2	8.9	
3	Screening for homologous recombination in ES cells using RT-PCR. *BioTechniques*, **1997**, 22, 22-4, 26	2.5	
2	Malignant Mesothelioma **2010**, 160-168		
1	Resistance to Targeted Therapies As a Result of Mutation(s) in the Target **2011**, 1-31		